Navigation Links
Sponsor-A-Scientist: New Option to Fund Biomedical Research
Date:9/5/2009

PHILADELPHIA, Sept. 4 /PRNewswire-USNewswire/ -- The Sbarro Health Research Organization (www.shro.org), a nonprofit center for cancer, cardiovascular and diabetes research located at Temple University in Philadelphia and the University of Siena, Italy, has launched Sponsor-A-Scientist (http://cgi.ebay.com/ws/eBayISAPI.dll?ViewItem&item=270448425234&ssPageName=ADME:L:LCA:US:1123), an innovative program that allows interested individuals to bid on e-Bay for a named fellowship to support a talented young scientist for one academic year.

The fellowship, which can be named in honor of a relative or loved one, will support a year of study under the direction of Antonio Giordano, M.D., Ph.D., the Founder and President of SHRO, the Director of the Sbarro Institute for Cancer Research and Molecular Medicine, and the Director of the Center for Biotechnology in the College of Science & Technology at Temple University in Philadelphia, PA. Dr. Giordano is also a 'Chiara fama' professor at the University of Siena, in Siena, Italy.

Despite recent increases in the budgets of the National Institutes of Health, which funds much of the country's biomedical research, dollars to pay for expensive research remain hard to come by for graduate and post-graduate students. Sponsor-A-Scientist's goal is to bring attention to and support for the work of young and gifted researchers, while giving the public an opportunity to be more directly involved in new and exciting medical discoveries.

"SHRO is at the forefront of molecular genetic discoveries in cancer and cardiovascular disease and in innovative methods to fund our important research," says Giord
'/>"/>

SOURCE Sbarro Health Research Organization
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Pelosi: Public Option Best Way to Control Costs, Promote Competition
2. United Concordia Dental Expands Benefit Options
3. New Options Available for the 13 Million Men Who Suffer from Testosterone Deficiency
4. Watchful waiting is a viable option for prostate cancer patients with low-risk tumors
5. Secca(R) Therapy - An Effective and Minimally Invasive Option for Treating Bowel Incontinence - Launched in the US
6. Home Dialysis a Good Option for Kidney Disease Patients
7. U.S. Senate Candidate Cheryle Jackson: Public Option Critical to Real Health Care Reform
8. Healthcare: Public Option Mirrors Other Government Insurance Plans
9. Georgia Reproductive Specialists Free Infertility Seminar: Fertility Options 101
10. Fattah Advocates D.C. March for Healthcare By the Supporters of Reform with Public Option
11. Stenting a Good Option for Left Main Heart Artery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
(Date:3/29/2015)... Ore. (PRWEB) March 29, 2015 Youth ... Marion counties in Oregon to assess the feasibility of ... with emotional and behavioral problems and their families. , ... to select participants that will be provided technical assistance ... Oregon counties join six other national awardees chosen by ...
(Date:3/29/2015)... 29, 2015 Final Cut Pro ... from Pixel Film Studios, entitled TranSports. , “TranSports ... for Final Cut Pro X,” said Christiana Austin, CEO ... tools needed to effortlessly transition using this cool sports ... new and uniquely styled transition pack for Final Cut ...
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 North ... several PT Online Continuing Education Courses . ... 10.0 hours of CME - TPTA, approval # 56399TX ... the evaluation of the shoulder complex - 10.5 hours ... Approved #56400TX , Examination and Treatment of the SI ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... Findings of a recent study suggests hunger may be ... researchers // studied 16 men who agreed to skip breakfast. ... evening. Participants were asked to consume sugary, salty or bitter ... not swallow the drinks, but instead spit them out after ...
... with chemo-resistant leukemia, a new drug is showing promising ... experimenting with bacteria-based recombinant immunotoxins. An immunotoxin is bioengineered ... part of the antibodies that are commonly used to ... encouraging results in a phase II study. ,Researchers ...
... Latest research shows the chickenpox vaccine loses some ... vaccination.// Parents are encouraged to vaccinate their children ... Consequently, researchers were prompted to further investigate the ... individuals. ,Researchers studied nearly 350 children ...
... common form of cancer in the United States. According to ... against colon cancer. In addition, soy protein may help minimize ... fed five different diets to female mice and followed their ... the effects of specific ingredients. Diet one contained milk protein, ...
... get up and get moving. Breast cancer survivors ... body esteem and better mood than sedentary breast ... ,Researchers compared 40 women who said they regularly ... cancer survivors. Regular exercisers reported significantly more positive ...
... depression may have an increased risk of heart disease ... than 93,600 older women who participated in the Women's ... long-term program designed to determine how biological and lifestyle ... and other health conditions. For this study, participants were ...
Cached Medicine News:
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... 27, 2015 BioCorRx, Inc. ( ... California is a healthcare solutions organization, which focuses ... at $22 billion in the U.S. alone. The Company created ... Naltrexone in a specially compounded form for outpatient surgical implantation. ... and New Zealand ) to the ...
(Date:3/27/2015)... 2015 Across the global healthcare landscape, the ... clinical development, market education, and regulatory compliance. As emerging ... function is expected to increase in prominence and follow ... According to research by benchmarking firm, Best Practices, LLC, ... to Medical Affairs. Among companies in India ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Aug. 16 Endologix, Inc. (Nasdaq: ELGX ... announced today that it has entered into a development ... for its balloon expandable stent technology. Evasc is a ... patented stent is made from cobalt chromium and is ...
... PRA International, a leading Clinical Research Organization, will host ... drug development on 24 August 2010 at 11:30 am ... PRA,s Scientific Affairs unit, will be the presenter. ... of the expensive failures that pharmaceutical companies experience during ...
Cached Medicine Technology:Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 2Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 3PRA International Hosts Audio Conference on CV Drug Development 2
Blood sedimentation rate analysis...
Blood sedimentation rate analysis...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
Medicine Products: